Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan;99(2):e18688.
doi: 10.1097/MD.0000000000018688.

Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report

Affiliations
Case Reports

Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report

Min Wei et al. Medicine (Baltimore). 2020 Jan.

Abstract

Introduction: Estrogen is a key factor in breast cancer carcinogenesis, and reductions in its synthesis can decrease breast cancer risk. Anastrozole can reduce plasma estrogen levels by inhibiting the enzyme aromatase, and is approved for adjuvant treatment of breast cancer. We report a case of pulmonary cryptococcosis in a patient who was treated with anastrozole for an early-stage tumor. This case is of special interest because the patient achieved a better curative effect after the administration of anastrozole was discontinued.

Patient concerns: A 61-year-old woman was found to have multiple pulmonary nodules on chest computed tomography (CT) after being treated for 5 months with anastrozole as an adjuvant breast cancer therapy. A biopsy of the largest lesion of the right lung showed cryptococcus fungal bodies with granulomatous inflammation, so the patient was diagnosed with pulmonary cryptococcosis. She was treated with fluconazole (400 mg/day) for 1 month, but a follow-up CT scan of chest showed no improvement.

Diagnosis: Pulmonary cryptococcosis.

Interventions: Because the pulmonary cryptococcosis was not improving, the administration of anastrozole was discontinued. Fluconazole was continued.

Outcomes: The pulmonary lesions diminished in size 2 months after discontinuing anastrozole. The patient continued taking fluconazole for a total of 6 months without re-administration of anastrozole, and the lesions of pulmonary cryptococcosis almost disappeared.

Conclusion: This case of pulmonary cryptococcosis may have been induced by a decrease in estrogen level caused by the aromatase inhibitor, anastrozole. Treatment of pulmonary cryptococcosis with concurrent anastrozole use may be ineffective, and it may be better to discontinue the aromatase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interests to disclose.

Figures

Figure 1
Figure 1
Findings of a chest CT. (A,B): The largest lesion was 14 mm in diameter. C: Findings of a chest CT after discontinuing the administration of anastrozole for 2 months.
Figure 2
Figure 2
Pathological findings of biopsy specimens from the largest lesion of the patient's right lung. Granulomatous change, fungus bodies of cryptococcus. A: HE staining, ×400 B: PAS staining, ×400.

Similar articles

Cited by

References

    1. Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008;15:278–90. - PubMed
    1. Moscetti L, Agnese FM, Sperduti I, et al. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 2015;101:469–73. - PubMed
    1. Nadkarni S, McArthur S. Oestrogen and immunomodulation: new mechanisms that impact on peripheral and central immunity. Curr Opin Pharmacol 2013;13:576–81. - PubMed
    1. Mohr JA, Long H, Mckown BA, et al. In vitro susceptibility of Cryptococcus neoformans to steroids. Sabouraudia 1972;10:171–2. - PubMed
    1. Trenti A, Tedesco S, Boscaro C, et al. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. Int J Mol Sci 2018;19:859. - PMC - PubMed

Publication types